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DESCRIPTION of CASE
A 
35-year-old woman became aware of a swelling in 
her neck about ten weeks before referral. She had 
been trying to conceive for ten months. She had 
had a missed abortion ﬁ  ve months earlier. Because of the 
neck swelling, her family doctor arranged thyroid function 
tests, which were in the thyrotoxic range on two occasions 
ﬁ  ve weeks apart: serum free thyroxine, 26 and 28 pmol/l 
(normal range, 11–23); serum free tri-iodothyronine, 10.9 
and 11 pmol/l (normal range, 3.5–6.5); serum thyroid-
stimulating hormone (TSH), <0.05 mU/l (normal range, 
0.3–4.1). 
Her previous medical history included a partial 
thyroidectomy for thyrotoxicosis at the age of 24. Other than 
a goitre, she had no symptoms except increased appetite 
and a slight tremor, which she had been aware of for about 
eight weeks. Following the missed abortion, she had two 
normal menstrual periods. Her only medication was folic acid 
supplements. She worked part-time and had a two-and-a-half-
year-old child.
On examination she was of average weight. Her hands 
were warm and moist. There was a ﬁ  ne tremor. A previous 
thyroidectomy scar was noted. The right lobe of the thyroid 
was palpable and felt smooth. There was a bruit over the 
right thyroid lobe on auscultation. She had lid retraction 
and lid lag but no other signs suggestive of thyroid-associated 
ophthalmopathy (TAO) (Figure 1). Her pulse rate was 100 
beats per minute and regular. Her blood pressure was 150/70 
mm Hg. The rest of the examination was normal. 
What Is the Cause of Her Thyrotoxicosis?
Thyrotoxicosis is no more than a descriptor for a pattern of 
biochemical abnormalities. Before considering treatment, 
it is the clinician’s task to deﬁ  ne the underlying cause, 
as an accurate diagnosis is an essential guide to the most 
appropriate treatment (Box 1). 
The most likely causes in this case were Graves disease, 
thyroiditis, toxic multinodular goitre (TMNG), and toxic 
adenoma. The hallmark of TMNG or toxic adenoma is 
the presence of one or more palpable thyroid nodules. In 
this case the patient had previously undergone a partial 
thyroidectomy and a vascular thyroid remnant was palpable 
on the right thyroid lobe. Post-partum thyroiditis occurs 
within 12 months of childbirth; a variant of this condition 
occurs after miscarriage. In this patient’s case post-partum 
thyroiditis was unlikely because her previous pregnancy was 
2.5 years earlier; however, the miscarriage ﬁ  ve months earlier 
may have been relevant. Viral thyroiditis is usually preceded 
by an upper respiratory tract infection and the thyroid gland 
is tender to touch; the absence of these features makes viral 
thyroiditis unlikely. “Silent” thyroiditis may present in this way 
and was a possibility here. 
Laboratory tests that may help differentiate between the 
different causes of thyrotoxicosis include a radiolabelled 
technetium or iodide thyroid scan (Figure 2), and 
measurement of anti–thyroid peroxidase (TPO) antibodies, 
TSH receptor antibodies, and inﬂ  ammatory markers (Table 
1). The thyrotoxic phase of thyroiditis is usually followed by 
spontaneous euthyroidism and in some cases hypothyroidism. 
Repeating thyroid function tests within a few weeks of the ﬁ  rst 
set may identify cases of thyroiditis.
In this case the prolonged time course of thyrotoxicosis, 
the presence of a vascular thyroid remnant, the persistently 
thyrotoxic thyroid function tests, and the elevated serum 
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Figure 1. The Patient’s Appearance at the Time of Presentation with 
Recurrent Thyrotoxicosis
Note that there are no signs of TAO, but the patient has minimal upper lid 
retraction (the upper lid should normally be halfway between the limbus 
and the pupil).PLoS Medicine  |  www.plosmedicine.org 1249
levels of TSH receptor antibodies (62 U/l; reference range, 
0–10) were in favour of a diagnosis of recurrent Graves 
disease. 
What Are the Effects of Thyrotoxicosis on Fertility 
and Risk of Abortion?
Menstrual irregularities occur in about 20% of thyrotoxic 
women [1]. Infertility is common in women with thyrotoxicosis 
even when they maintain ovulatory cycles [1]. Thyrotoxicosis 
also increases the risk of miscarriage to 26% [2].
How Should This Patient Be Treated?
There are three treatment options for thyrotoxicosis due to 
Graves disease: radioiodine (131I) therapy, thyroidectomy, 
and anti-thyroid drugs [3]. 131I therapy is safe and effective, 
but pregnancy should be deferred for 4–6 months after 
treatment as there are theoretical risks of fetal abnormalities. 
Most national regulatory authorities recommend avoidance 
of close contact with adults for a few days and with children 
and pregnant women for 2–3 weeks. 131I therapy was not 
appropriate for this patient because she wished to proceed 
with pregnancy as soon as possible and she had a two-and-a-
half-year-old child, who would be difﬁ  cult to care for after 131I 
therapy. 
A second thyroidectomy is worthy of consideration, but 
involves general anaesthesia and a period of recuperation of a 
few weeks and therefore disruption of family and professional 
life. The risks of damage to the recurrent laryngeal nerves 
and parathyroid glands after a second thyroidectomy are 
considerably greater than after a ﬁ  rst operation and are 
of the order of 5%–10%. Because of these considerations, 
thyroidectomy was not felt to be a suitable option.
Anti-thyroid drugs (carbimazole, methimazole, and 
propylthiouracil) restore euthyroidism within a few weeks of 
initiation of treatment [4]. Minor side effects (such as skin 
rashes) occur in about 5% of cases. Agranulocytosis is rare 
(~0.4%), but the consequences are life threatening and all 
patients on anti-thyroid drugs must be made aware of this 
complication (Box 2). All anti-thyroid drugs have been used 
and are acceptable in pregnancy. 
Congenital anomalies have been reported in association 
with anti-thyroid drugs, but the increase in risk above 
background is very marginal. The risks of aplasia cutis and 
choanal and oesophageal atresia may be slightly lower 
with propylthiouracil than with other anti-thyroid drugs 
(choanal and oesophageal atresia, scalp defects, minor facial 
anomalies, and psychomotor delay compose an embryopathy 
implicated with methimazole use). But because the evidence 
is inconclusive and the additional risk minimal, all three 
drugs are widely used in pregnancy. The lowest dose of anti-
thyroid drug that maintains euthyroidism should be used 
in women who wish to become or are already pregnant, 
in order to avoid fetal hypothyroidism and fetal goitre 
formation. 
In this case propylthiouracil was used initially, at a dose 
of 50 mg four times per day. The patient was advised to 
take contraceptive measures until euthyroidism. Four weeks 
later her thyroid function tests had improved: serum free 
thyroxine, 13 pmol/l; serum total tri-iodothyronine, 2.5 
nmol/l (normal range, 1.34–2.73); serum TSH, <0.05 mU/l. 
The dose of propylthiouracil was reduced to 25 mg four times 
per day, and the patient was advised that she could start trying 
to conceive. 
What Are the Risks of TAO?
TAO is a complication that many patients fear. It can be 
disﬁ  guring and difﬁ  cult to treat [3]. If there are no clinical 
features of TAO at presentation, the risk of developing it 
in future is approximately 15%. Smoking is an important 
predisposing factor. As this patient was a non-smoker the 
probability of developing TAO is less than 10%.
What Monitoring Is Required during Pregnancy?
The dose of anti-thyroid drug usually needs to be decreased 
during pregnancy, and often Graves disease remits completely 
Table 1. Diagnostic Tests for Identifying the Cause of Thyrotoxicosis
Condition Technetium  99 or Iodide Scan Anti-TPO Antibodies Anti-TSH Receptor 
Antibodies
Inﬂ  ammatory Markers 
(ESR/CRP)
Graves disease Increased uniform uptake 70% positive >95% positive Normal
TMNG “Hot” and “cold” areas 0%–5% positive <5% positive Normal
Toxic adenoma Single “hot” area 0%–5% positive <5% positive Normal
Thyroiditis—viral Decreased uptake 0%–5% positive <5% positive Elevated
Thyroiditis—silent/post-partum Decreased uptake >90% positive <5% positive Normal
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
DOI: 10.1371/journal.pmed.0020370.t001
Box 1. Causes of Thyrotoxicosis
Common causes of thyrotoxicosis in a young female
• Graves disease
• Thyroiditis
• Toxic multinodular goitre
• Toxic adenoma
• Iodine excess 
Other rare causes of thyrotoxicosis
• Hyperemesis gravidarum
• Choriocarcinoma
• TSH-producing pituitary adenoma
• Iatrogenic thyrotoxicosis
• Factitious thyrotoxicosis
• Struma ovarii
• Metastatic follicular thyroid cancer
• Thyroid hormone resistance syndrome
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and the medication can be withdrawn. This is probably due to 
the overall immunosuppressive effect of pregnancy. 
Monitoring of free thyroid hormone concentrations is of 
paramount importance during pregnancy and should be 
performed every 4–6 weeks, or more frequently if thyroid 
status is changing. The biochemical target is to achieve and 
maintain maternal serum free thyroxine levels at or slightly 
above the upper limit of normal, using the lowest dose of 
anti-thyroid drug possible. TSH receptor antibodies should be 
measured in the third trimester because positivity is predictive 
of neonatal thyrotoxicosis [5]. 
When the mother (as in this case) has a functioning 
thyroid gland or remnant in situ, maternal thyroid function 
mirrors that of the fetus. If there are concerns about fetal 
thyrotoxicosis (e.g., because maternal hyperthyroidism 
proves difﬁ  cult to control), fetal heart rate monitoring 
should be undertaken. A persistent fetal tachycardia 
greater than 160 beats per minute is suggestive of fetal 
thyrotoxicosis. In cases where fetal thyrotoxicosis is 
diagnosed, monitoring of fetal growth and fetal goitre by 
ultrasound is imperative. In most cases the fetus can be 
treated satisfactorily by adjusting the dose of anti-thyroid 
drug in the mother and by following the fetal response 
clinically and by ultrasound.
What Are the Risks to the Fetus in a Woman with 
Graves Disease?
Poor control of maternal hyperthyroidism is associated with 
signiﬁ  cant obstetric complications including miscarriage 
(26%), low birth weight, prematurity, (pre-)eclampsia, and 
possibly congenital malformations [6]. After the fetal thyroid 
matures (from 20 weeks of gestation onwards), maternal TSH 
receptor antibodies may act on the fetal thyroid to cause fetal 
thyrotoxicosis and goitre. The risk of fetal thyrotoxicosis is 
about 1% of all pregnancies in women with Graves disease, 
and if untreated, fetal mortality may be as high as 24%. 
Overtreatment may lead to hypothyroidism in the fetus, 
which is associated with subtle neurocognitive deﬁ  cits later 
on in life, particularly if the hypothyroidism occurs in the 
ﬁ  rst trimester [7]. Fetal goitre can develop as a result of fetal 
thyrotoxicosis or fetal hypothyroidism and in severe cases can 
obstruct labour.
What Are the Risks of Recurrence of Thyrotoxicosis 
after Delivery?
The risk of relapse of maternal thyrotoxicosis is high in 
the post-partum period (up to 80%), and close monitoring 
is required. Anti-thyroid drugs can be used safely during 
breastfeeding [8].
Prenatal Counselling of Women with Graves Disease 
Pregnancy is a common concern among women of 
childbearing age who are receiving treatment for Graves 
disease. Some women may elect to have deﬁ  nitive treatment 
before pregnancy, which can be either a thyroidectomy or 
131I therapy. The advantage of these treatment options is 
that the risk of maternal thyrotoxicosis during pregnancy 
is reduced, if not eliminated. Fertility is not affected by 
131I therapy for thyrotoxicosis, but pregnancy should be 
deferred for 4–6 months after 131I therapy, although the 
basis of this recommendation is largely empirical. The risk 
of fetal and neonatal thyrotoxicosis is not eliminated by 
previous thyroidectomy or 131I therapy. The most important 
advice to women who have a previous history of thyroid 
dysfunction is to work with their practitioner to ensure that 
thyroid function tests are normal at the time of conception 
and throughout pregnancy.
Box 2. Patient Information Leaﬂ  et Used 
by the Author to Remind Patients Receiving 
Anti-Thyroid Drugs of the Potential Complication 
of Agranulocytosis
“You have been started on a drug called Carbimazole/
Methimazole/Propylthiouracil to control the activity of your 
thyroid gland. This is important treatment and Carbimazole/
Methimazole/Propylthiouracil is a well established drug that 
has been used for many years. The great majority of people 
treated with Carbimazole/Methimazole/Propylthiouracil have no 
problems whatsoever.
“Some people occasionally develop a rash—if this happens 
please consult your doctor as soon as possible; you need not 
discontinue the drug unless he/she tells you to do so.
“More rarely, Carbimazole/Methimazole/Propylthiouracil 
affects white cells in the blood, in which case you would be likely 
to develop a very severe sore throat and to feel ill with a fever. 
If this happens while you are on Carbimazole/Methimazole/
Propylthiouracil treatment you must attend either your family 
doctor or the hospital on the same day, to have your blood count 
checked. Take no more tablets until the blood count has been 
checked. If your white blood count is normal you can carry on 
with the Carbimazole/Methimazole/Propylthiouracil. If your 
white blood count is abnormal your family doctor or the hospital 
will need to deal with this problem urgently.
“Please keep this with you in case you need to show it to your 
doctor.”
DOI: 10.1371/journal.pmed.0020370.g002
Figure 2. Technetium 99 Thyroid Uptake Scans 
(A) Normal.
(B) Graves disease: diffuse increased uptake in both thyroid lobes.
(C) TMNG: “hot” and “cold” areas of uneven uptake.
(D) Toxic adenoma: increased uptake in a single nodule with suppression 
of the surrounding thyroid.
(E) Thyroiditis: decreased or absent uptake. 
(Image: Giovanni Maki)
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DISCUSSION
Aetiology of Graves Disease
Graves disease is an autoimmune condition and is mediated 
by stimulatory autoantibodies to the TSH receptor. There is 
a signiﬁ  cant genetic component to the aetiology of Graves 
disease, although environmental factors and stress also seem 
to confer risk [3]. Typically, the thyroid gland of patients with 
Graves disease is diffusely enlarged and vascular. 
Toxic Multinodular Goitre
TMNG may also run in families. The pathogenesis is 
unknown. The disease begins with the formation of a single 
or few colloid nodules, and over a period of several years 
these become larger and more numerous. Some nodules 
are functioning and gradually acquire autonomy. With 
the passage of time serum TSH declines and may become 
undetectable until at a later stage serum free thyroid 
hormones rise. The hyperthyroidism of TMNG is usually mild 
and tends to occur in middle life or later. Toxic adenomas 
are benign neoplasms of the thyroid that are autonomous. In 
some cases they arise because of somatic mutations that lead 
to constitutive activation of the TSH receptor. As with TMNG, 
the hyperthyroidism tends to be mild. 
Thyroiditis
Thyroiditis is due to an inﬂ  ammatory process affecting the 
thyroid epithelium. Unlike other causes of thyrotoxicosis, 
there is no increased synthesis of thyroid hormones; instead, 
stored thyroid hormones in colloid are released into the 
circulation because of the leaky epithelium. The thyrotoxic 
phase of thyroiditis may be followed by a hypothyroid phase 
a few weeks later, but as a rule the patient recovers and 
euthyroidism ensues without any intervention. 
Thyroiditis may occur after a viral infection (referred to 
as subacute or De Quervain thyroiditis), in which case the 
patient typically has a viral sore throat, the thyroid is tender, 
and inﬂ  ammatory markers (erythrocyte sedimentation 
rate and C-reactive protein) are raised. “Silent” thyroiditis 
is autoimmune and characterised by positive anti-TPO 
antibodies. 
Investigating the Cause of Thyrotoxicosis
In many cases of thyrotoxicosis the aetiology will be apparent 
from information that can be obtained from the history 
and clinical examination. In cases where there is doubt, 
additional investigations are indicated. Direct measurement 
of TSH receptor antibody levels is not widely available, but 
can be very valuable as modern assays are highly sensitive and 
speciﬁ  c. TSH receptor antibodies can occasionally be positive 
in post-partum thyroiditis (this seems to be particularly rare 
in Europe, though reported in North America and Japan), 
and in cases of doubt a thyroid scan showing no uptake of 
radioisotope is diagnostic of thyroiditis [9]. TSH receptor 
antibody measurement is indicated in pregnancy to assess the 
risks of fetal and neonatal thyrotoxicosis. Anti-TPO antibodies 
occur in a signiﬁ  cant proportion of the normal population, 
and this limits the use of this test. High concentrations of 
anti-TPO antibodies are present in silent and post-partum 
thyroiditis. Radioisotope scans are useful in identifying the 
cause of thyrotoxicosis (Figure 2), but should be avoided in 
pregnancy.
Treatment of Thyrotoxicosis
The treatment of thyrotoxicosis depends on the underlying 
cause. Anti-thyroid drugs are effective in Graves disease, 
TMNG, and toxic adenoma (Table 2), but not in thyroiditis 
because the latter is not associated with increased de novo 
synthesis of thyroid hormones. 
After a course of anti-thyroid drug treatment, remission 
may be expected in Graves disease as a result of the 
Learning Points 
• Thyrotoxicosis is not a diagnosis, merely a biochemical result. 
An accurate clinical diagnosis encompassing the aetiology is 
imperative for optimal management. 
• The most common cause of thyrotoxicosis in women of 
childbearing age is Graves disease.
• Thyrotoxicosis impairs fertility, and thyroid status should 
be assessed in women with secondary infertility or recurrent 
abortions.
• Three treatments are available for thyrotoxicosis due to Graves 
disease: anti-thyroid drugs, 131I therapy, and thyroidectomy. 
The right treatment is that which suits the patient’s individual 
circumstances best.
• 131I therapy is an absolute contraindication in pregnancy. 
Anti-thyroid drugs may be used safely, and the dose should be 
titrated to the minimum dose that maintains normal maternal 
thyroid hormone levels.
• The hyperthyroidism of Graves disease usually remits after the 
ﬁ  rst trimester, and anti-thyroid drugs can be withdrawn; however, 
relapse of maternal thyrotoxicosis in the post-partum period is 
common.
• Uncontrolled maternal hyperthyroidism can lead to fetal 
thyrotoxicosis with devastating effects on the fetus. Fetal 
thyrotoxicosis can be treated satisfactorily by appropriate 
manipulation of the maternal dose of anti-thyroid drug and 
careful fetal monitoring.
Table 2. Response of Common Causes of Thyrotoxicosis to 131I Therapy and Anti-Thyroid Drugs
Condition 131I Therapy Incidence of Hypothyroidism 
after 131I Therapy
Anti-Thyroid Drugs Remission Rate after Course 
of Anti-Thyroid Drugs 
Graves disease Effective 90% Effective 40%
TMNG/toxic adenoma Effective 10% Effective 0%
Thyroiditis Ineffective — Ineffective —
DOI: 10.1371/journal.pmed.0020370.t002
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immunosuppressive effect of anti-thyroid drugs on synthesis 
of TSH receptor antibodies, but relapse is the rule in cases of 
TMNG or toxic adenoma. 
131I therapy is effective for Graves disease, TMNG, and toxic 
adenoma. 131I therapy is ineffective in thyroiditis because 
iodine uptake is reduced or absent in this condition (Figure 
2). Most patients with Graves disease develop permanent 
hypothyroidism after 131I therapy, whereas most patients with 
TMNG and toxic adenoma do not. 131I therapy is associated 
with a small risk of exacerbation of new development of TAO, 
particularly in smokers. 
Thyroiditis may require symptomatic treatment with beta 
blockers during the thyrotoxic phase. 
The type of thyroidectomy (subtotal versus total) for 
Graves disease as primary treatment has been the subject 
of controversy for some years. The argument in favour of 
total thyroidectomy is that the risk of recurrence of the 
thyrotoxicosis is eliminated, and that if performed by skilled 
thyroid surgeons the probability of hypoparathyroidism 
and vocal cord palsy is no greater than for a subtotal 
thyroidectomy [10]. A subtotal thyroidectomy, on the other 
hand, provides the best chance of any treatment for Graves 
disease for long-term euthyroidism without the need for 
thyroxine or other treatments for thyrotoxicosis. 
The choice of treatment for Graves disease should be 
tailored to the needs of the individual patient, but also depends 
on local facilities, surgical expertise, and patient choice.  
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